CONMED (CNMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.38
- EPS estimate
- $1.11
- EPS surprise
- +24.32%
- Revenue surprise
- +1.75%
- Revenue
- $343.5M
- Revenue estimate
- $337.6M
- Reported
- Jul 29, 2026
CONMED reported Q2 2026 results on July 29, 2026. Earnings per share were $1.38, ahead of the $1.11 estimate by 24.32%. Revenue was $343.5 million, above the $337.6 million consensus by 1.75%. Compared with Q2 2025, EPS rose 20% from $1.15, while revenue was nearly flat, up 0.4% from $342.3 million.
The table shows steady growth in annual EPS: $2.65 in 2022, $3.45 in 2023, $4.16 in 2024 and $4.61 in 2025. The first half of 2026 adds up to $2.27, about 8% more than the $2.10 of a year earlier. Q4 is usually the strongest quarter, and Q4 2025 set the highs here at $1.43 per share and $373.2 million in revenue. The low in the table is Q4 2022, at $0.42 per share, which missed the estimate by 53.56%. CONMED beat the EPS estimate in 18 of the last 20 quarters; the other miss was Q4 2023, at 4.62% below.
CONMED reported Q3 results between October 25 and November 5 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the EPS growth of the first half carries into the third quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $1.11 | $1.38 | +24.32% | $343.5M | SEC |
| Q1 2026 | Apr 29, 2026 | $0.82 | $0.89 | +8.72% | $317.0M | SEC |
| Q4 2025 | Jan 28, 2026 | $1.32 | $1.43 | +8.01% | $373.2M | SEC |
| Q3 2025 | Nov 5, 2025 | $1.06 | $1.08 | +1.65% | $337.9M | SEC |
| Q2 2025 | Jul 30, 2025 | $1.12 | $1.15 | +2.38% | $342.3M | SEC |
| Q1 2025 | Apr 30, 2025 | $0.81 | $0.95 | +17.08% | $321.3M | SEC |
| Q4 2024 | Feb 5, 2025 | $1.20 | $1.34 | +11.42% | $345.9M | SEC |
| Q3 2024 | Oct 30, 2024 | $1.02 | $1.05 | +2.63% | $316.7M | SEC |
| Q2 2024 | Jul 31, 2024 | $0.91 | $0.98 | +7.68% | $332.1M | SEC |
| Q1 2024 | Apr 24, 2024 | $0.74 | $0.79 | +7.06% | $312.3M | SEC |
| Q4 2023 | Jan 31, 2024 | $1.11 | $1.06 | −4.62% | $327.0M | SEC |
| Q3 2023 | Oct 25, 2023 | $0.84 | $0.90 | +7.30% | $304.6M | SEC |
| Q2 2023 | Jul 26, 2023 | $0.79 | $0.83 | +4.55% | $317.7M | SEC |
| Q1 2023 | Apr 26, 2023 | $0.60 | $0.66 | +10.46% | $295.5M | SEC |
| Q4 2022 | Feb 2, 2023 | $0.90 | $0.42 | −53.56% | $250.9M | SEC |
| Q3 2022 | Oct 26, 2022 | $0.75 | $0.77 | +2.39% | $275.1M | SEC |
| Q2 2022 | Jul 27, 2022 | $0.75 | $0.76 | +0.72% | $277.2M | SEC |
| Q1 2022 | May 4, 2022 | $0.62 | $0.70 | +13.21% | $242.3M | SEC |
| Q4 2021 | Jan 26, 2022 | $1.03 | $1.07 | +4.06% | $274.0M | SEC |
| Q3 2021 | Oct 27, 2021 | $0.75 | $0.80 | +6.70% | $248.8M | SEC |
Quarterly revenue
Frequently asked questions
When did CONMED (CNMD) last report earnings?
CONMED last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did CNMD beat earnings estimates?
Yes. CONMED reported EPS of $1.38 for Q2 2026 against a $1.11 estimate — a 24.32% beat.
How much revenue did CNMD report last quarter?
CONMED reported $343.5M in revenue for Q2 2026, against a consensus estimate of $337.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.